Revised SPCs: Tecentriq (atezolizumab) 840 and 1200 mg concentrate for solution for infusion

Hyperthyroidism (common) and hypertension (v common) have been added to SPCs as adverse effects of atezolizumab combination therapy.

Source:

electronic Medicines compendium